Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MImAbs operates a fully integrated R&D platform specializing in the generation and characterization of therapeutic antibodies for immunotherapy. The company supports the translation of promising academic or industry-discovered targets into drug candidates by providing services such as antibody engineering, bioproduction at milligram-to gram-scale, development of bispecifics and ADCs, and comprehensive pharmacology testing. Their focus areas are cancer and inflammatory diseases. They do not appear to have their own proprietary clinical pipeline but rather enable clients’ programs through preclinical development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MImAbs.